Later today, I hope to attend the Clean-Tech Meetup–an event which,  Gov. Deval Patrick, has said, “brings together innovative leaders from across the Commonwealth, the country and the globe to grow businesses, advance technologies and expand the adoption of clean energy sources.”

             As described on the Clean Tech Meetup Web site,  “through  Clean Energy Week and the Conference on Clean Energy in Boston,”  Massachusetts has been “steadily growing” a community of clean energy innovators and implementers.   “Now, we’re using what we’ve learned to bring you an event focusing on connecting people in intimate settings—instead of panels or keynotes.”

• Major Energy Consumers, Utilities, Leading Cleantech Companies, and other companies looking to form partnerships will meet providers of innovative clean energy services, products, and technologies.
• Investors will meet over 50 companies from more than 10 countries, hear from emerging clean energy companies, and talk with major energy users about their needs for clean energy technologies.
• Emerging Clean Energy Companies will talk with potential investors, strategic partners, and customers.

View the conference program.

Innovation Tour:  The conference also includes a tour of “cool companies and organizations” that will be holding open houses”from  Kendall Square to the Seaport Innovation District,” on Wednesday.  View the Tour participants.

I’m pleased that my friend and informal client, Christine Adamow, President and CEO of EuphorbUS,   announced today that her company, , a  “tree-based”  biofuel company that  has operated in East Africa since 2007,  will soon open its first operating site in North America in Hawaii.

The Meetup  is pricey, with registration $400+ for  participants and  $500-$1000 for presenters, who are selected by the conference organizations. (Might say I was surprised that the organizers called the event a meetup– because most “meetups” I’ve heard of are free or nearly so).   Held at the Boston Convention Center, it  runs through Wednesday.

—Anita M. Harris

SHANAHAN NAMED VP OF BUSINESS DEVELOPMENT

—One of the newest international companies to expand into Cambridge is Ariana (R)  Pharma–a 2003 spin-out of the Pasteur Institute in Paris.  Its  subsidiary, Ariana Data Intelligence, Inc., located in the Cambridge Innovation Center at 1 Broadway,  will provide novel non-statistical clinical data analysis technology to pharma and the FDA,  Ariana announced today.

The technology,  “Knowledge Extraction and Management Technology (KEM)” is aimed at reducing cost, bias, and risk in clinical trials.

“The US pharma and biotech markets tend  to be early technology adopters and are searching for better data analytics tools to advance personalized medicine using all the new biomarker, genomic, proteomic and metabolomic data now being generated,” said  Dr. Mohammad Afshar, Ariana’s President and CEO.

KEM   “is the only FDA-tested technology that  can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials,” Afshar said.

A “unique” association rules-based (non-statistical) analytical technology, KEM  finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect, according to Afshar.  KEM thus optimizes clinical trial inclusion/exclusion criteria, thereby lowering the number of patients needed to reach clinical endpoints and saving sponsors both time and cash, and reducing clinical drug development risk.

In conjunction with the opening, Ariana has appointed James M. Shanahan as Vice President  of Business Development.  Shanahan was previously a co-founder and is currently a  board member of SynDevRx, Inc., an oncology-focused biotech company. He was also a co-founder and VP Corporate Development of JAM Technologies, Inc.

Ariana offers something “special and desperately needed “by the pharmaceutical industry, Shanahan said.   “Companies spend tens of millions generating data.  Now, it’s all about making sense of that data.  KEM identifies useful, complex biological relationships that statistics routinely miss.”

More information is available at  http://www.arianapharma.com/  .

–Anita M. Harris

Chicago-based  Healthbox is now accepting applications for a new,  $50,000 three-month  health tech business accelerator program  to start August 13,  in Cambridge.

In the program, up to ten  selected New England-based companies will receive: $50,000 in seed capital;  collaborative workspace;  access to a mentor network of industry experts  and strategic guidance, according to Dan Phillips, a director of  Sandbox Industries, Healthbox’ parent company, who attended Venture Cafe in the Cambridge Innovation Center last week.  The  program will conclude with a high-profile conference in November at which each participant will pitch to an audience of investors and healthcare leaders from across the country.

Healthbox  is one of the first business accelerator programs in the healthcare industry to support a platform for  innovation among seed-stage companies, according to the Sandbox Website.

“Massachusetts’ world-renowned academic institutions, cutting-edge provider systems and strong investor community make it an ideal location for a healthcare accelerator to stimulate the ecosystem and support new ideas,” said Healthbox founder Nina Sharif, in a press release.  “We are looking forward to working with New England’s most promising healthcare entrepreneurs to help them gain traction in the industry and develop sustainable businesses.”

Massachusetts Blue Cross Blue Shield Venture Funds will be among those providing financial support for the Cambridge program, according to Ryan Boxill of the BCBSMA Finance Development Program.

Earlier this year, Healthbox hosted its first program in Chicago.  According to a company press release, ten healthcare technology startups were selected from hundreds of applicants and, within three months,  the teams were able to evolve their business models and establish new partnerships and pilots. The program was supported by strategic partners including  Boston-based HLM Venture Partners; Ascension Health;  BlueCross BlueShield Venture Partners; California HealthCare Foundation; Merge Healthcare;  Merrick Ventures; Sandbox Industries and Walgreens.

David Nichols of CareWire, a Minnesota-based company that participated in the Healthbox Chicago program said: “This program has helped us really focus in on our core value, rapidly test assumptions and launch pilots with new customers.”

Mark Hall, the CEO of New Jersey-based United Preference, another Healthbox Chicago participant, added “Things that take 6 months or 12 months in other environments, we’ve been able to achieve in 2 to 4 weeks here.”

According to its Website, Sandbox Industries creates, invests  in and explores new businesses that it believes could change markets. Through a new model of business development that “helps rather than harass entrepreneurs,”  it aims  to “grow successful companies through collaboration and knowledge sharing…redefining the way great ideas are generated and transformed into successful companies.”

Applications are currently being accepted on the Healthbox website at www.healthboxaccelerator.com/apply. For information and announcements about the program, visit www.healthboxaccelerator.com and follow the Twitter feed – @health_box

—Anita M. Harris

Anita Harris is a writer and journalist based at the Cambridge Innovation Center in Kendall Square, Cambridge.

For entrepreneurs seeking venture capital funding, there’s good news—and there’s bad news. The good news is that  it’s easier now than at any time in the last ten years to get relatively small amounts of seed money. The bad news is that it’s harder to obtain “A Round” or additional series funding after that.

That was the consensus of  three Boston area venture capitalists who spoke at the Cambridge Innovation Center on  Wednesday, May 2.  Moderator Ben Hron of  law firm McCarter -English, which sponsored the event, asked the VCs  how the 2008 economic downturn  has impacted the VC industry;  where things stand now,  and what they foresee for the future.

Impact of the recession
A changing industry
Jo Tango, founder and partner of Kepha Partners, which invests in early stage companies, said that for many VC firms, this is a period of innovation. “We call it VC 2.0,”  he quipped to the audience of  entrepreneurs.  The VC industry, which started in about 1980, used to be dominated by approximately 20 major firms; today, there are more smaller, more specialized VC firms, he said.

David Beisel, co-founder and partner of  NextView Ventures, a dedicated seed-stage venture capital firm focused on Internet startups, said that the downturn has “facilitated a  maturation process,” which he likened to what happened in the beer industry in the 1990s.

That is, “You had to be either one of the biggest, like Anheuser-Busch—or a microbrewery.” Mid-size companies like Genesee fell by the wayside.

Likewise,  today,  he said, “VC firms are no longer trying to be all things to all entrepreneurs; they’re taking a dedicated approach.  Recently, four or five firms raised more than $1B but mid-sized firms are struggling.”

CA Webb, Executive Director of the New England Venture Capital Association, said that considering this a time of “introspection and innovation” is “optimistic…The reality is that the industry is taking a hard look at itself. Some say that the ‘sky is falling,’ because there’s less money being invested; this means that some firms will shut down. Those that succeed will need to articulate clearly just what they are willing to offer and to whom.”

Tango pointed out that “Innovation [in the VC industry] creates a challenge for entrepreneurs because VC firms are “all over the map,” and “it’s difficult to know which one is right for [a particular startup]. It’s easier now to get seed money–but terms are often more difficult to distinguish.”

Current trends
In asking the panelists for their views on the current venture funding situation, Hron shared Q1 2012 statistics showing  a large number of deals but a drop in total funding compared with previous quarters– in indicating fewer “megadeals.”  “Should entrepreneurs should be optimistic because of the number of deals or pessimistic about the size of the deals?” he asked.

Fewer large deals
Tango responded that one reason for the decline in large deals has to do with the number of deals VCs have previously closed.  In the current economic climate, he explained, it’s difficult raise a stream of money. In a recent study of five VC Web sites, his firm found that many VCs are already sitting on the boards of 10-17 companies in which they have invested. “If you’re fundraising…if you’re already on 15 boards, you need to spend your time fund raising,” not sitting on additional boards.

Smaller investments
Beisel described what he called a longer term trend:  in some sectors, especially digital media, companies don’t need to raise as much money for initial funding as in other sectors–so at earlier stages, the venture community is reacting by not writing $5M checks but rather $1M or .5 M.

In Webb’s view, “seeding is now like the old Series A funding: there is a lot of seed money to go around but Series A is now looking like the old series C “(IE–difficult to come by).

Follow-on funding can be problematic.
Tango agreed –describing a firm that backed 20 companies with seed money but told him it will provide only 2 % of those with Series A funding.  He added that the situation is even more complicated because even at the “seed stage,”different VCs require different terms.

In fact, he recommended, “Ninety per cent of startups should be bootstrapped (funded by self, friends and family) because other investors expect that they will get their money out within a few years. “With VC funding, you’re becoming a fiduciary…taking on ‘credit card debt’ that you will need to pay back.”

In Beisel’s view, before taking any money from VCs, an entrepreneur needs to know how outsiders view the firm, the reputation of the VC firm, which partner will be best for the company, and whether the firm usually adds to series funding or “will you be one of the 98% that get dropped?”

Health care vs. other  investment
Citing a decline in financing for health care ventures in Massachusetts compared with increased financing for Internet and mobile technology, Hron asked if investors are seeking short-term gains as instead of  taking the long view required for biotechnology and pharma payback.

Webb responded that one reason for the slowdown in health care company funding is that the US Food and Drug Administration is taking longer to approve products so the horizons for investors are longer. As a result, investors are shifting toward healthcare technology, “big data” and products that will bring a quicker return.

In Beisel’s view, “Over the last ten years the returns for health care investment have not been that great; health care is now even more challenging. But VCs won’t shift to other spaces; the money just won’t get raised.”

Long -term trends
According to Hron, the data suggest a rise in VC investing in Washington State, Texas, and Illinois. “Are we seeing the rise of a national VC community or is this a blip?” he asked. “And will VC investors look at companies nationwide?”

Tango and Beisel agreed that large investors are looking at companies nationally and internationally–especially in the Internet space.

They also agreed that it’s unlikely that VCs will spring up in Kansas or in “third-tier American cities,” as Beisel; put it.  In Tango’s view, “they will still be centered in Boston, NY and California.”  Beisel pointed out that that VC firms are on the rise in nations like Argentina and Eastern Europe.  According to Webb, “Capital clusters around academic institutions: You won’t see much density elsewhere.”

Crowd sourcing
Regarding the  recent passage of legislation allowing corporate fundraising through crowd sourcing, panelists expressed concerns about possibilities for fraud and entry of organized crime; and also  that unsophisticated investors might not know that seasoned professionals expect to lose money on most  investments—in hopes that a few will have big payoffs.

Asked by Hron if VCs will look askance at companies raising initial funding through crowd sourcing, Beisel said  that it’s fine to get seed money wherever you can but a “real company” will need institutional investors in order to grow large.

In Tango’s view, “Your source of funding depends on what you want to accomplish: Do you just want to get money…or are you looking for series of VC rounds, advice and support?”

PANELIST BIOs

David Beisel – David is Co-Founder and Partner of NextView Ventures, a dedicated seed-stage venture capital firm focused on investments in internet startups.  Previously he was an investor at both Venrock and Masthead Venture Partners, where he served on the boards of BlogHer and Gazelle.  Prior to joining Masthead, he co-founded Sombasa Media, an e-mail marketing company which was successfully acquired by About.com and subsequently became a division of Primedia (NYSE: PRM), where he served as Vice President of Marketing.  He is also the founder of the Web Innovators Group, a quarterly entrepreneur-focused event which attracts nearly a thousand attendees.  David blogs atwww.GenuineVC.com.

Jo Tango – Jo is Founder and Partner of Kepha Partners, an early-stage venture capital firm.   Previously, Jo spent was a General Partner at Highland Capital Partners, where he worked for nearly nine year, and before that he spent five years with Bain & Company.  Jo has invested in the e-commerce, search engine, Internet ad network, wireless, supply chain software, storage, database, security, on-line payments and data center virtualization spaces.  He has been a founding or first institutional investor in Azuki Systems, Bit9, ExaGrid, StreamBase Systems, Vertica Systems (acquired by Hewlett-Packard), Virtual Iron (acquired by Oracle) and VoltDB, getting involved nearly always at the company inception phase. Other investments include Ask Jeeves (Nasdaq: ASKJ), Digital Market (acquired by Agile Software), and NextCard (Nasdaq: NXCD).

C.A. Webb – C.A. became the Executive Director of the New England Venture Capital Association in January 2012.  Members of the NEVCA include more than 700 venture capital professionals from over 100 firms that collectively manage more than $50 billion in capital.  C.A. has spent her career in entrepreneurial roles with mission driven, early stage and high growth organizations. Her work has focused on breakthrough business models in a diverse array of industries including retail and packaged goods (Whole Foods Market), consumer internet technology (Care.com), sustainability (Preserve Products), historic preservation (Trinity Boston Foundation), public education (Boston Collegiate Charter School), and publishing (Fast Company magazine

Earlier this week,  I had the privilege of attending the tenth annual “BIO-IT World Conference and Expo,” at which some 2500  information technology professionals participated in a 12-track program featuring more than 200 presentations on scientific and technologic developments.

From  keynote speakers Jill Mesirov, PhD, and Martin Leach, PhD,  respectively the Associate Director and Chief Information Officer  of the Harvard-MIT Broad Institute,  I learned that exponential increases  in computing power promise to bring personalized medicine –allowing highly individualized diagnosis and treatment –to doctors offices within ten years. I also learned how hard it is to keep track of the petabytes  ( a PBs is a unit of information equal to one quadrillion  bytes, or 1024 terabytes )  used to keep it all going.

Mesirov announced the upcoming launch of “Genome Space“–a new Web-based technology to help scientists make sense of and collaborate in using such data.

And in a talk entitled “BIG,”  Leach described the difficulty of defining “big data,” because the amount of available information is growing so rapidly.   He described an event held recently at the Broad to celebrate the Institute’s ability to store and analyze ten pedabytes of data –his glee soon tempered by  his recollection that in 1993, NIH’s Institute of Medicine was thrilled with its ability store 16 gigabytes–which anyone can now do on a cell phone.

Today,  Leach said, we are  seeing “increasing big data with a decreasing footprint.” [that is, smaller systems needed for gathering and retrieval].

Mentioning that he has an autistic son and would like to be able to figure out what causes the disorder, Leach  asked, “Why is there no Google search for data, no way to access thousands of data repositories?

“We need a new application ecosystem and a breed of data scientist who knows how and where to push this data, ” he said.  He predicted that there will soon be 50 thousand jobs in the  “big data” arena.

In the exhibit hall,  I was pleased to see that  see that Wingu, headquartered in the Cambridge Innovation Center, where I work, had been nominated for a best of show award for its pharmaceutical, contract research and academic collaboration software.

The winners, announced last night, were Recentris, Opscode, Clear Trial, and Cambridge Semantics. [More info at http://www.bio-itworld.com/2012/04/26/2012-best-of-show-winners.html]. Best Practice Grand Prizes went to big Pharma: Merck, Pfizer, and Merck KGaA (Germany)  went to and two genomics organizations, BGI Shenzhen and the University of Utah/Omicia. http://www.bio-itworld.com/2012/04/25/bio-it-world-announces-winners-2012-best-practices-awards.html.

BIO-IT World is sponsored by  Insight Pharma Reports, Samsung, and the Portland Group. It runs through April 27, 2012.

—Anita M. Harris

In an effort to harness and allow sharing of exponentially-developing genetic data, the Broad Institute will launch “Genome Space,”–a co-operative Web based tool aimed at “frictionless” data transfer, later this week.

So said Jill Merisov, PhD, the Broad’s associate director and Chief Informatics officer,  in a keynote speech at the opening of the Bio-IT World conference  yesterday,  in Boston. The Broad is a Harvard-MIT research center located in Kendall Square, Cambridge.

In her talk, Merisov pointed out that just ten years ago,  scientists announced that they had identified all of the genes present in human beings.  Since then, researchers  have discovered 30 million genetic variations among 1000 different individuals, 3000 genetically-related disease traits, and a multitude of cancer types. Such findings are  now being used to determine the genetic bases of  many diseases, to develop treatments for those diseases, and to determine for which patients particular treatments are likely to be effective. In another ten years,  she said, such “personalized medicine” will be commonly used by doctors, in clinics.

These advances are due in large part to less expensive,  increasingly sophisticated and sensitive computer technologies that have led to an “explosion”  of data ,  to less “noisy”  data, and to new, international ways of  reviewing  the data, Merisov explained.  Scientists can now buy the technology and carry out sequencing in their own labs and “”computing is now integral to every aspect of biomedical research.”

But these developments also mean that there are now  seven-to-ten  thousand bioinformatics tools available for download on the Web and five thousand databases–many of  which are “out of reach”  for scientists who do not have sophisticated programming skills.

The new tool  “bridges the gaps between bioinformatics tools, making it possible for [scientists ] to move data smoothly between these tools, leveraging the available analyses and visualizations in each of these tools,” according to the Genome Space Web site.

Genome Space also allows for data storage in the Amazon cloud [a computing platform of Amazon.com]  and “provides necessary file format transformations whenever a scientists selects an analysis or visualization within one of the tools.

The GenomeSpace project is a collaboration of the Mesirov and Regev laboratories at the Broad Institute; the Chang laboratory at Stanford University; the Ideker laboratory at the University of California, San Diego; the Nekrutenko laboratory at Pennsylvania State University; the Segal laboratory at the Weizmann Institute of Science; and the Haussler and Kent laboratories at the University of California, Santa Cruz. GenomeSpace is funded by the National Human Genome Research Institute, with additional support from Amazon Web Services, according to the Genome Space Web site.

The Bio-IT Conference Expo 2012   goes through April 26.

–Anita M. Harris

At a Loss for Word

I spent the day trying to write and wrestling with Word. I’m a decade late with this rant, but today it got me.

I can barely remember why, but I loved Word Perfect. It was so well named from a writer’s perspective. It was the document software in which I  learned to type and for a long time the standard for writers and PR people and everyone who wanted to share a common language. It could catch my thoughts as they leapt fully formed (if out of context) from my brow;  store sidebars without getting sidetracked; set up and organize the page, stylize it with heads and subheads and put things in the order I wished; insert exported images and show me how they looked; accept Tom Swifties and newly minted puns; and help me express my thoughts in my own voice.

Then came PCs and laptops and Word slipped in under the tent flap and became the standard. Let’s face it, by comparison, Word bites and . . . behaves in other infantile ways. (You know what I mean, but you’ll see in a minute *** why I can’t type it.)

Who made Microsoft geeks the emperors of syntax and spelling and slang (Oh my!)? Who taught them to spell and keep up with language? Why are they the Wizards of Word? Why don’t they know that the basics (page layout, font, ability to insert, addition of typographical and graphic marks) should be doable without leaving the page? How come they use spellcheck to block current spelling of workplan and wasteland and  inhouse that don’t have hyphens- and make us change our use of speech to accommodate that quirk? What kind of bleeping editing program does not challenge words like ‘pubicrelations’ when you meant public relations, or f*** and s*** when you meant to write funk or shim? C’mon, that’s adolescent geekspeak for gotcha, smartyhosen!

What’s your favorite Word bugaboo?  While I’m at it, why do they call it Windows when they’re opaque, and laid on top of what you need to see for reference? For puzzle fans there are seven words flagged here in red by Word (none were on Lenny Bruce’s list).  Can you find them?

All for today. Rest easy  (See? If they knew syntax they’d have flagged that for easily!).

Guest blogger Ann Getman is a writer, painter and public relations consultant based in Cambridge, MA.
New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.